620 related articles for article (PubMed ID: 31355677)
21. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients.
Patil R; Shanmukhaiah C; Gogtay NJ; Pandey P; Patil K; Jijina F; Madkaikar M
J Thromb Haemost; 2024 Apr; 22(4):1024-1030. PubMed ID: 38160726
[TBL] [Abstract][Full Text] [Related]
22. Emicizumab for the prevention of bleeds in hemophilia A.
Mahlangu J
Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
[No Abstract] [Full Text] [Related]
23. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
25. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
[TBL] [Abstract][Full Text] [Related]
26. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors.
Escobar M; Bullano M; Mokdad AG; Caicedo J; Schultz BG; Fan Q; Verma S
Expert Rev Hematol; 2023 Jun; 16(6):467-474. PubMed ID: 37114481
[TBL] [Abstract][Full Text] [Related]
27. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.
Valentino LA; Khair K
Expert Rev Hematol; 2020 Jul; 13(7):731-743. PubMed ID: 32573295
[TBL] [Abstract][Full Text] [Related]
28. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data.
Cho H; Yoo KY; Shin JY; Lee EK; Choi B
J Thromb Haemost; 2024 Jun; 22(6):1640-1648. PubMed ID: 38395359
[TBL] [Abstract][Full Text] [Related]
29. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
30. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
[TBL] [Abstract][Full Text] [Related]
31. Emicizumab for hemophilia A with factor VIII inhibitors.
Young G; Callaghan M; Dunn A; Kruse-Jarres R; Pipe S
Expert Rev Hematol; 2018 Nov; 11(11):835-846. PubMed ID: 30278802
[TBL] [Abstract][Full Text] [Related]
32. Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.
Takeyama M; Furukawa S; Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Mizumachi K; Noguchi-Sasaki M; Shima M; Nogami K
Thromb Haemost; 2021 Oct; 121(10):1289-1298. PubMed ID: 33641138
[TBL] [Abstract][Full Text] [Related]
33. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
[TBL] [Abstract][Full Text] [Related]
35. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.
Shimonishi N; Sasai K; Ogiwara K; Furukawa S; Nakajima Y; Mizumachi K; Yada K; Takeyama M; Shima M; Mizuno N; Nogami K
Int J Hematol; 2023 Dec; 118(6):690-698. PubMed ID: 37803190
[TBL] [Abstract][Full Text] [Related]
37. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms.
Lillicrap D; Fijnvandraat K; Young G; Mancuso ME
Expert Rev Hematol; 2020 Apr; 13(4):313-321. PubMed ID: 32186928
[No Abstract] [Full Text] [Related]
38. Emicizumab (Hemlibra) for subcutaneous prophylaxis in hemophilia A.
Med Lett Drugs Ther; 2019 May; 61(1572):77-79. PubMed ID: 31169801
[No Abstract] [Full Text] [Related]
39. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
Kruse-Jarres R; Peyvandi F; Oldenburg J; Chang T; Chebon S; Doral MY; Croteau SE; Lambert T; Kempton CL; Pipe SW; Ko RH; Trzaskoma B; Dhalluin C; Bienz NS; Niggli M; Lehle M; Paz-Priel I; Young G; Jiménez-Yuste V
Blood Adv; 2022 Dec; 6(24):6140-6150. PubMed ID: 35939785
[TBL] [Abstract][Full Text] [Related]
40. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
